Clinical Trial Update: A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of hSTC810 with paclitaxel in relapsed or refractory extensive-stage small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• hSTC810

Snippet

Sponsor: STCube, Inc. | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED